DKK 411.6
(6.85%)
Year | Total Liabilities | Total Liabilities Growth |
---|---|---|
2023 | 145.62 Million DKK | -5.87% |
2022 | 154.69 Million DKK | 2.68% |
2021 | 150.66 Million DKK | 30.82% |
2020 | 115.16 Million DKK | 8.28% |
2019 | 106.35 Million DKK | 0.0% |
Year | Total Liabilities | Total Liabilities Growth |
---|---|---|
2024 Q1 | 146.88 Million DKK | 0.87% |
2024 Q2 | 146.88 Million DKK | 0.0% |
2023 FY | 145.62 Million DKK | -5.87% |
2023 Q3 | 145.62 Million DKK | 24.47% |
2023 Q2 | 116.98 Million DKK | 0.0% |
2023 Q4 | 145.62 Million DKK | -0.0% |
2023 Q1 | 116.98 Million DKK | -24.37% |
2022 Q4 | 154.69 Million DKK | 0.0% |
2022 FY | 154.69 Million DKK | 2.68% |
2022 Q3 | 154.69 Million DKK | 0.0% |
2022 Q1 | - DKK | 0.0% |
2021 FY | 150.66 Million DKK | 30.82% |
2020 FY | 115.16 Million DKK | 8.28% |
2019 FY | 106.35 Million DKK | 0.0% |
Name | Total Liabilities | Total Liabilities Difference |
---|---|---|
ALK-Abelló A/S | 2.27 Billion DKK | 93.61% |
Bavarian Nordic A/S | 4.01 Billion DKK | 96.372% |
Genmab A/S | 3.67 Billion DKK | 96.042% |
Novo Nordisk A/S | 207.92 Billion DKK | 99.93% |
Orphazyme A/S | 5.07 Million DKK | -2772.209% |
Pharma Equity Group A/S | 42.4 Million DKK | -243.413% |
Zealand Pharma A/S | 1.6 Billion DKK | 90.933% |